ArticleBMJ open quality2025
Reducing drug-related harm by triggering proactive outreach.
Article in BMJ open quality, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-related deaths (DRDs) remain a global issue, with Scotland reporting the second-highest rate per million population. Although some areas have seen improvements, DRDs continue to rise in parts of the Scottish Highlands. Proactive outreach to those at highest risk is believed to reduce harm. This project tested and implemented a risk identification tool-the Trigger Checklist (TC)-to initiate assertive outreach in a remote Highland area by September 2023.The Model for Improvement was used to structure the improvement process. This included collaborative exploration of the problem and solution, development of the TC, devising a family of measures and Plan, Do, Study, Act cycles to structure interactive learning and refinement of the TC and outreach process. Data were collected on the number of completed TC, the percentage of those outreached within 48 hours and the number of days between incidents of non-fatal overdoses (NFOD). Timely staff experience feedback was gathered using a visual facial analogue scale.A standardised TC was devised and tested. 48 TCs were received over 8 months. Of those 100% (n=48) were assertively outreached within 48 hours of a TC referral. The median number of days between NFOD increased from 6.5 days (January-August 2022) to 23 days (September 2022-August 2023). There was an increase in the number of days between incidents of NFOD locally, with more than 90 days between two events (previously the maximum number reached was 48). For the duration of the project, the locality did not receive a DRD notification.There is a need to further test and standardise the use of the TC in other areas frequented by those most at risk of drug-related harm, such as the remote and rural emergency department.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.